{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:30:27Z","timestamp":1783434627993,"version":"3.54.6"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cancergen.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T01:31:41Z","timestamp":1399685501000},"page":"195-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania"],"prefix":"10.1016","volume":"207","author":[{"given":"Ram\u016bnas","family":"Janavi\u010dius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilius","family":"Rudaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugnius","family":"Mickys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Elsakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Gri\u0161kevi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.cancergen.2014.05.002_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdp116","article-title":"BRCA in breast cancer: ESMO clinical recommendations","volume":"20","author":"Balmana","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/IGC.0b013e3181dbd1a5","article-title":"Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer","volume":"20","author":"Trainer","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrclinonc.2010.175","article-title":"The role of BRCA mutation testing in determining breast cancer therapy","volume":"7","author":"Trainer","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-med-010910-110221","article-title":"Therapeutic approaches for women predisposed to breast cancer","volume":"62","author":"Nathanson","year":"2011","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.cancergen.2014.05.002_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMcp071286","article-title":"Clinical practice. Management of an inherited predisposition to breast cancer","volume":"357","author":"Robson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cancergen.2014.05.002_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/CCO.0b013e3283139173","article-title":"Hereditary breast cancer: from bench to bedside","volume":"20","author":"De Greve","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib8","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.acra.2008.06.006","article-title":"MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach","volume":"15","author":"Granader","year":"2008","journal-title":"Acad Radiol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1\u2212 and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2014.05.002_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jmg.2008.062232","article-title":"Risk reducing mastectomy: outcomes in 10 European centres","volume":"46","author":"Evans","year":"2009","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib13","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.cancergen.2014.05.002_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","article-title":"Founder BRCA1\/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control","volume":"1","author":"Janavi\u010dius","year":"2010","journal-title":"EPMA J"},{"key":"10.1016\/j.cancergen.2014.05.002_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-005-5150-6","article-title":"High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families","volume":"94","author":"Gronwald","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cancergen.2014.05.002_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-008-0166-3","article-title":"Novel and common BRCA1 mutations in familial breast\/ovarian cancer patients from Lithuania","volume":"117","author":"Janavi\u010dius","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cancergen.2014.05.002_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1399-0004.2010.01404.x","article-title":"The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania","volume":"78","author":"Elsakov","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/(SICI)1098-1004(1999)14:1<92::AID-HUMU23>3.0.CO;2-2","article-title":"Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258","volume":"14","author":"Csokay","year":"1999","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cancergen.2014.05.002_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10689-004-2758-3","article-title":"High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia","volume":"4","author":"Tikhomirova","year":"2005","journal-title":"Fam Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib20","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1086\/302922","article-title":"Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer","volume":"66","author":"Gorski","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1034\/j.1399-0004.2001.600611.x","article-title":"Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families","volume":"60","author":"Oszurek","year":"2001","journal-title":"Clin Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1399-0004.2010.01439.x","article-title":"The contribution of founder mutations in BRCA1 to breast cancer in Belarus","volume":"78","author":"Uglanitsa","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10689-007-9120-5","article-title":"Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia","volume":"6","author":"Sokolenko","year":"2007","journal-title":"Fam Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1897-4287-7-5","article-title":"High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients","volume":"7","author":"Suspitsin","year":"2009","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.cancergen.2014.05.002_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cancergen.2014.05.002_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1373\/clinchem.2007.098764","article-title":"Rapid and sensitive detection of BRCA1\/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms","volume":"54","author":"De Leeneer","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.cancergen.2014.05.002_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmg.2012.12.007","article-title":"Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation","volume":"56","author":"Janavicius","year":"2013","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1471-2350-12-147","article-title":"Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia","volume":"12","author":"Plakhins","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib29","first-page":"329","article-title":"Variation in BRCA1 cancer risks by mutation position","volume":"11","author":"Thompson","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cancergen.2014.05.002_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10549-007-9571-2","article-title":"Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast\/ovarian cancer patients","volume":"107","author":"Konstantopoulou","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cancergen.2014.05.002_bib31","first-page":"271","article-title":"Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study","volume":"58","author":"Neuhausen","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ejhg.2010.203","article-title":"On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations","volume":"19","author":"Hamel","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/gtmb.2009.0001","article-title":"Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals","volume":"13","author":"Kaufman","year":"2009","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.cancergen.2014.05.002_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-011-1338-5","article-title":"Prevalence of C282Y, H63D, and S65C mutations in hereditary HFE-hemochromatosis gene in Lithuanian population","volume":"91","author":"Kucinskas","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10689-006-9101-0","article-title":"Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden","volume":"6","author":"Einbeigi","year":"2007","journal-title":"Fam Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2350-9-83","article-title":"Five recurrent BRCA1\/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families","volume":"9","author":"Krajc","year":"2008","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N","article-title":"BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics","volume":"77","author":"Wagner","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-06-3297","article-title":"Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis","volume":"67","author":"Carvalho","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2014.05.002_bib39","first-page":"e96","article-title":"BRCA1 variant of unknown significance (ACMG category 3) in 2 unrelated Polish\/Ukrainian families","volume":"19","author":"Hastings","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib40","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1200\/JCO.2008.17.8228","article-title":"Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance","volume":"26","author":"Spearman","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib41","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2007.13.2779","article-title":"Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis\u2014a report from the kConFab Investigators","volume":"26","author":"Spurdle","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/humu.9226","article-title":"BRCA1 and BRCA2 mutations in women with familial or early-onset breast\/ovarian cancer in the Czech Republic","volume":"23","author":"Foretova","year":"2004","journal-title":"Human Mutat"},{"key":"10.1016\/j.cancergen.2014.05.002_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2407-8-140","article-title":"Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and\/or ovarian cancer","volume":"8","author":"Machackova","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2007.09.035","article-title":"High frequency of BRCA1\/2 germline mutations in consecutive ovarian cancer patients in Poland","volume":"108","author":"Brozek","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.canlet.2010.07.013","article-title":"Non-founder BRCA1 mutations in Russian breast cancer patients","volume":"298","author":"Iyevleva","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cancergen.2014.05.002_bib46","first-page":"263","article-title":"BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland","volume":"19","author":"Ratajska","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cancergen.2014.05.002_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/GCO.0b013e328332dca3","article-title":"BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications","volume":"22","author":"Kurian","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib48","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jnci\/91.14.1241","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer","volume":"91","author":"Warner","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2014.05.002_bib49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.05.002_bib50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ijc.20162","article-title":"A\u00a0high proportion of founder BRCA1 mutations in Polish breast cancer families","volume":"110","author":"Gorski","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13353-011-0040-6","article-title":"Prevalence of the most frequent BRCA1 mutations in Polish population","volume":"52","author":"Brozek","year":"2011","journal-title":"J\u00a0Appl Genet"},{"key":"10.1016\/j.cancergen.2014.05.002_bib52","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cancergen.2014.05.002_bib53","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","article-title":"Limited family structure and BRCA gene mutation status in single cases of breast cancer","volume":"297","author":"Weitzel","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cancergen.2014.05.002_bib54","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast and Ovarian v.1.2013. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf. Accessed October 1, 2013."}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221077621400088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221077621400088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:39:02Z","timestamp":1761896342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221077621400088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S221077621400088X"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.05.002","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}